Campbell Capital Management Inc. decreased its stake in CVS Health Co. (NYSE:CVS) by 0.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 115,442 shares of the pharmacy operator’s stock after selling 1,022 shares during the period. CVS Health accounts for about 4.0% of Campbell Capital Management Inc.’s holdings, making the stock its 6th biggest holding. Campbell Capital Management Inc.’s holdings in CVS Health were worth $8,685,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. Dodge & Cox grew its stake in CVS Health by 0.5% during the fourth quarter. Dodge & Cox now owns 15,960,473 shares of the pharmacy operator’s stock worth $1,090,100,000 after purchasing an additional 77,629 shares during the period. Norges Bank acquired a new stake in CVS Health during the fourth quarter worth approximately $964,912,000. Dimensional Fund Advisors LP grew its stake in CVS Health by 0.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 12,152,434 shares of the pharmacy operator’s stock worth $829,977,000 after purchasing an additional 32,967 shares during the period. Caisse DE Depot ET Placement DU Quebec grew its stake in CVS Health by 33.3% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 10,118,403 shares of the pharmacy operator’s stock worth $691,087,000 after purchasing an additional 2,525,912 shares during the period. Finally, Nordea Investment Management AB grew its stake in CVS Health by 3.4% during the fourth quarter. Nordea Investment Management AB now owns 9,123,988 shares of the pharmacy operator’s stock worth $623,168,000 after purchasing an additional 296,234 shares during the period. 74.21% of the stock is owned by institutional investors.
CVS stock traded down $0.77 during midday trading on Thursday, hitting $73.72. The company’s stock had a trading volume of 81,694 shares, compared to its average volume of 7,071,797. The stock’s 50-day moving average price is $72.43 and its 200 day moving average price is $68.51. The company has a quick ratio of 0.67, a current ratio of 0.95 and a debt-to-equity ratio of 0.89. CVS Health Co. has a 1 year low of $55.36 and a 1 year high of $77.23. The stock has a market cap of $96.67 billion, a price-to-earnings ratio of 12.24, a PEG ratio of 1.72 and a beta of 0.82.
The company also recently announced a quarterly dividend, which will be paid on Monday, May 3rd. Shareholders of record on Friday, April 23rd will be paid a $0.50 dividend. The ex-dividend date of this dividend is Thursday, April 22nd. This represents a $2.00 annualized dividend and a dividend yield of 2.71%. CVS Health’s payout ratio is presently 28.25%.
In other CVS Health news, EVP Alan Lotvin sold 25,836 shares of the business’s stock in a transaction on Friday, January 8th. The stock was sold at an average price of $75.00, for a total value of $1,937,700.00. Following the sale, the executive vice president now directly owns 18,469 shares in the company, valued at $1,385,175. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig bought 3,000 shares of the stock in a transaction on Wednesday, February 17th. The stock was purchased at an average price of $72.00 per share, for a total transaction of $216,000.00. Over the last 90 days, insiders sold 594,375 shares of company stock worth $44,673,602. Corporate insiders own 0.46% of the company’s stock.
CVS has been the subject of several recent research reports. Guggenheim restated a “neutral” rating on shares of CVS Health in a report on Tuesday, March 23rd. SVB Leerink boosted their price objective on CVS Health from $73.00 to $80.00 and gave the company a “market perform” rating in a report on Monday, December 14th. Finally, Jefferies Financial Group raised CVS Health from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research report on Friday, January 8th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $82.08.
About CVS Health
CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services.
Further Reading: How liquidity affects the bid-ask spread
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.